Overview Dividends

(ZBH) Zimmer Biomet Holdings - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US98956P1021

Knee, Hip, Sports Medicine, Trauma, Craniomaxillofacial

EPS (Earnings per Share)

EPS Growth (3y CAGR): 0.39%
EPS Trend (3y Corr): 25.2%

Last SUE: 0.69σ
Qual. Beats: 0

Revenue

Revenue Growth (3y CAGR): 3.41%
Revenue Trend (3y Corr): 72.9%

Last SUE: -0.89σ
Qual. Beats: 0

Risk via 10d forecast
Volatility	25.0%
Value at Risk 5%th	36.5%
Relative Tail Risk	-11.40%

Reward TTM
Sharpe Ratio	-0.62
Alpha	-25.26

Character TTM
Hurst Exponent	0.436
Beta	0.281
Beta Downside	0.299

Drawdowns 3y
Max DD	38.66%
Mean DD	19.36%
Median DD	22.46%

Description: ZBH Zimmer Biomet Holdings October 16, 2025

Zimmer Bioper (NYSE: ZBH) is a global medical-technology firm that designs, manufactures and markets a broad portfolio of orthopedic and reconstructive solutions-including knee and hip implants, sports-medicine devices, trauma and extremities products, and craniomaxillofacial/ thoracic fixation systems. Its offerings span hardware, bone-cement and data-driven surgical platforms that serve orthopedic surgeons, neurosurgeons, hospitals and specialty distributors worldwide.

In fiscal 2023 the company reported roughly $7.6 billion in revenue, with a 13 % operating margin-both modestly above the industry median of ~11 % for large orthopedic OEMs. Growth is being driven by three measurable levers: (1) an aging U.S. and European population that raises demand for joint replacement (U.S. joint-replacement procedures are projected to rise ~2 % annually through 2030); (2) expanding sales in emerging markets where per-capita orthopedic spend is still low but growing at ~8 % CAGR; and (3) incremental revenue from data-analytics services tied to its digital surgery platform, which now contributes ~3 % of total sales. A material risk is ongoing Medicare reimbursement pressure, which could compress margins if policy changes reduce payment rates for joint-replacement procedures.

For a deeper, data-driven assessment of ZBH’s valuation dynamics-including forward-looking cash-flow models and peer-adjusted multiples-explore the detailed analyst toolkit on ValueRay.

ZBH Stock Overview

Market Cap in USD	17,949m
Sub-Industry	Health Care Equipment
IPO / Inception	2001-07-25
Return 12m vs S&P 500	-30.9%
Analyst Rating	3.45 of 5

ZBH Dividends

Metric	Value
Dividend Yield	1.08%
Yield on Cost 5y	0.70%
Yield CAGR 5y	0.74%
Payout Consistency	97.1%
Payout Ratio	11.9%

ZBH Growth Ratios

Metric	Value
CAGR 3y	-7.47%
CAGR/Max DD Calmar Ratio	-0.19
CAGR/Mean DD Pain Ratio	-0.39
Current Volume	2441.4k
Average Volume	1859k

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income (805.2m TTM) > 0 and > 6% of Revenue (6% = 480.7m TTM)

FCFTA 0.07 (>2.0%) and ΔFCFTA 1.08pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 42.84% (prev 17.02%; Δ 25.82pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.07 (>3.0%) and CFO 1.69b > Net Income 805.2m (YES >=105%, WARN >=100%)

Net Debt (6.82b) to EBITDA (2.38b) ratio: 2.87 <= 3.0 (WARN <= 3.5)

Current Ratio 2.43 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (198.8m) change vs 12m ago -2.07% (target <= -2.0% for YES)

Gross Margin 71.44% (prev 71.78%; Δ -0.34pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 35.44% (prev 34.97%; Δ 0.47pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 4.61 (EBITDA TTM 2.38b / Interest Expense TTM 282.8m) >= 6 (WARN >= 3)

Altman Z'' 4.05

(A) 0.15 = (Total Current Assets 5.83b - Total Current Liabilities 2.40b) / Total Assets 23.49b

(B) 0.49 = Retained Earnings (Balance) 11.52b / Total Assets 23.49b

(D) 1.05 = Book Value of Equity 11.24b / Total Liabilities 10.72b

Total Rating: 4.05 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 68.67

1. Piotroski 7.0pt = 2.0

2. FCF Yield 6.46% = 3.23

3. FCF Margin 19.99% = 5.00

4. Debt/Equity 0.64 = 2.30

5. Debt/Ebitda 2.87 = -1.58

6. ROIC - WACC (= 0.36)% = 0.45

7. RoE 6.42% = 0.54

8. Rev. Trend 72.86% = 5.46

9. EPS Trend 25.23% = 1.26

What is the price of ZBH shares?

As of November 18, 2025, the stock is trading at USD 88.64 with a total of 2,441,428 shares traded.
Over the past week, the price has changed by -0.10%, over one month by -13.03%, over three months by -13.36% and over the past year by -20.83%.

Is ZBH a buy, sell or hold?

Zimmer Biomet Holdings has received a consensus analysts rating of 3.45. Therefor, it is recommend to hold ZBH.

Strong Buy: 5
Buy: 6
Hold: 16
Sell: 1
Strong Sell: 1

What are the forecasts/targets for the ZBH price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	103.4	16.7%
Analysts Target Price	103.4	16.7%
ValueRay Target Price	83.6	-5.7%

ZBH Fundamental Data Overview November 17, 2025

Market Cap USD = 17.95b (17.95b USD * 1.0 USD.USD)
P/E Trailing = 22.3102
P/E Forward = 10.5152
P/S = 2.2406
P/B = 1.3968
P/EG = 0.9144
Beta = 0.61
Revenue TTM = 8.01b USD
EBIT TTM = 1.30b USD
EBITDA TTM = 2.38b USD
Long Term Debt = 7.51b USD (from longTermDebt, last quarter)
Short Term Debt = 600.0m USD (from shortTermDebt, last quarter)
Debt = 8.11b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.82b USD (from netDebt column, last quarter)
Enterprise Value = 24.77b USD (17.95b + Debt 8.11b - CCE 1.29b)
Interest Coverage Ratio = 4.61 (Ebit TTM 1.30b / Interest Expense TTM 282.8m)
FCF Yield = 6.46% (FCF TTM 1.60b / Enterprise Value 24.77b)
FCF Margin = 19.99% (FCF TTM 1.60b / Revenue TTM 8.01b)
Net Margin = 10.05% (Net Income TTM 805.2m / Revenue TTM 8.01b)
Gross Margin = 71.44% ((Revenue TTM 8.01b - Cost of Revenue TTM 2.29b) / Revenue TTM)
Gross Margin QoQ = 72.05% (prev 71.49%)
Tobins Q-Ratio = 1.05 (Enterprise Value 24.77b / Total Assets 23.49b)
Interest Expense / Debt = 0.93% (Interest Expense 75.4m / Debt 8.11b)
Taxrate = 17.19% (48.0m / 279.2m)
NOPAT = 1.08b (EBIT 1.30b * (1 - 17.19%))
Current Ratio = 2.43 (Total Current Assets 5.83b / Total Current Liabilities 2.40b)
Debt / Equity = 0.64 (Debt 8.11b / totalStockholderEquity, last quarter 12.76b)
Debt / EBITDA = 2.87 (Net Debt 6.82b / EBITDA 2.38b)
Debt / FCF = 4.26 (Net Debt 6.82b / FCF TTM 1.60b)
Total Stockholder Equity = 12.54b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.43% (Net Income 805.2m / Total Assets 23.49b)
RoE = 6.42% (Net Income TTM 805.2m / Total Stockholder Equity 12.54b)
RoCE = 6.51% (EBIT 1.30b / Capital Employed (Equity 12.54b + L.T.Debt 7.51b))
RoIC = 5.46% (NOPAT 1.08b / Invested Capital 19.80b)
WACC = 5.10% (E(17.95b)/V(26.06b) * Re(7.05%) + D(8.11b)/V(26.06b) * Rd(0.93%) * (1-Tc(0.17)))
Discount Rate = 7.05% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -2.38%
[DCF Debug] Terminal Value 78.61% ; FCFE base≈1.46b ; Y1≈1.49b ; Y5≈1.66b
Fair Price DCF = 147.2 (DCF Value 29.18b / Shares Outstanding 198.2m; 5y FCF grow 2.13% → 3.0% )
EPS Correlation: 25.23 | EPS CAGR: 0.39% | SUE: 0.69 | # QB: 0
Revenue Correlation: 72.86 | Revenue CAGR: 3.41% | SUE: -0.89 | # QB: 0

Additional Sources for ZBH Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle